Cargando…
Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells
OBJECTIVE: To study the biological characteristics of paclitaxel resistant endometrial carcinoma cells and its mechanism of drug resistance. METHOD: The paclitaxel resistant cell lines were established by high-dose paclitaxel (TAX) injection. The IC50 of paclitaxel was determined by CCK-8 assay in I...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098927/ https://www.ncbi.nlm.nih.gov/pubmed/30175145 http://dx.doi.org/10.1155/2018/8372085 |
_version_ | 1783348561315889152 |
---|---|
author | Ding, Jie Li, Mengxiong Deng, Liuzhi Li, Tian |
author_facet | Ding, Jie Li, Mengxiong Deng, Liuzhi Li, Tian |
author_sort | Ding, Jie |
collection | PubMed |
description | OBJECTIVE: To study the biological characteristics of paclitaxel resistant endometrial carcinoma cells and its mechanism of drug resistance. METHOD: The paclitaxel resistant cell lines were established by high-dose paclitaxel (TAX) injection. The IC50 of paclitaxel was determined by CCK-8 assay in Ishikawa and Ishikawa-TAX. The cell cycle and apoptosis rate were detected by flow cytometry. Western blot was used to detect the expression of p-AKT and p-p70S6K. The expression of drug resistance-related genes Pgp and MDR1 was determined by RT-PCR. Cell viability was determined by soft agarose assay and invasive ability in vitro by transwell assay. RESULTS: Paclitaxel and NVP-BEZ235 cotreatment group can further inhibit the clonogenicity and invasion of Ishikawa and Ishikawa-TAX cells compared with paclitaxel alone and NVP-BEZ235 treatment group. Paclitaxel and NVP-BEZ235 cotreated groups increased the apoptosis rate of Ishikawa and increased G0/G1 phase arrest in both cells. Paclitaxel alone significantly inhibited p-AK and p-p70 S6K protein expression in Ishikawa and Ishikawa-TAX cells and the inhibition was enhanced by NVP-BEZ235 when cotreated with paclitaxel. CONCLUSION: Paclitaxel can inhibit Ishikawa and Ishikawa-TAX cell via PI3K/Akt/mTOR signaling pathway. Paclitaxel and NVP-BEZ235 cotreatment can enhance the inhibitory effect. |
format | Online Article Text |
id | pubmed-6098927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-60989272018-09-02 Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells Ding, Jie Li, Mengxiong Deng, Liuzhi Li, Tian Biomed Res Int Research Article OBJECTIVE: To study the biological characteristics of paclitaxel resistant endometrial carcinoma cells and its mechanism of drug resistance. METHOD: The paclitaxel resistant cell lines were established by high-dose paclitaxel (TAX) injection. The IC50 of paclitaxel was determined by CCK-8 assay in Ishikawa and Ishikawa-TAX. The cell cycle and apoptosis rate were detected by flow cytometry. Western blot was used to detect the expression of p-AKT and p-p70S6K. The expression of drug resistance-related genes Pgp and MDR1 was determined by RT-PCR. Cell viability was determined by soft agarose assay and invasive ability in vitro by transwell assay. RESULTS: Paclitaxel and NVP-BEZ235 cotreatment group can further inhibit the clonogenicity and invasion of Ishikawa and Ishikawa-TAX cells compared with paclitaxel alone and NVP-BEZ235 treatment group. Paclitaxel and NVP-BEZ235 cotreated groups increased the apoptosis rate of Ishikawa and increased G0/G1 phase arrest in both cells. Paclitaxel alone significantly inhibited p-AK and p-p70 S6K protein expression in Ishikawa and Ishikawa-TAX cells and the inhibition was enhanced by NVP-BEZ235 when cotreated with paclitaxel. CONCLUSION: Paclitaxel can inhibit Ishikawa and Ishikawa-TAX cell via PI3K/Akt/mTOR signaling pathway. Paclitaxel and NVP-BEZ235 cotreatment can enhance the inhibitory effect. Hindawi 2018-08-05 /pmc/articles/PMC6098927/ /pubmed/30175145 http://dx.doi.org/10.1155/2018/8372085 Text en Copyright © 2018 Jie Ding et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Ding, Jie Li, Mengxiong Deng, Liuzhi Li, Tian Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title | Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title_full | Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title_fullStr | Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title_full_unstemmed | Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title_short | Study on Biological Characteristics and Mechanism of Paclitaxel Induced Drug Resistance in Endometrial Carcinoma Cells |
title_sort | study on biological characteristics and mechanism of paclitaxel induced drug resistance in endometrial carcinoma cells |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098927/ https://www.ncbi.nlm.nih.gov/pubmed/30175145 http://dx.doi.org/10.1155/2018/8372085 |
work_keys_str_mv | AT dingjie studyonbiologicalcharacteristicsandmechanismofpaclitaxelinduceddrugresistanceinendometrialcarcinomacells AT limengxiong studyonbiologicalcharacteristicsandmechanismofpaclitaxelinduceddrugresistanceinendometrialcarcinomacells AT dengliuzhi studyonbiologicalcharacteristicsandmechanismofpaclitaxelinduceddrugresistanceinendometrialcarcinomacells AT litian studyonbiologicalcharacteristicsandmechanismofpaclitaxelinduceddrugresistanceinendometrialcarcinomacells |